Among the millions who turned to GLP-1 medications seeking relief from diabetes or excess weight, hundreds now allege they lost something far more precious: their sight. Lawsuits filed against Novo Nordisk and Eli Lilly claim that Ozempic, Wegovy, and Mounjaro triggered sudden, severe vision loss in patients who were never warned such a risk existed. The cases arrive at a moment when these drugs have become cultural phenomena, reminding us that the wider a medicine's reach, the more consequential even its rarest shadows become.
Hundreds sue GLP-1 makers over alleged vision loss linked to Ozempic, Wegovy, Mounjaro
Hundreds of patients report sudden vision loss or blindness after taking GLP-1 medications, resulting in significant disability and quality-of-life impacts.
Health & Medicine